Cargando…
Dosimetric verification of IMPT using a commercial heterogeneous phantom
The purpose of this study was to propose a verification method and results of intensity‐modulated proton therapy (IMPT), using a commercially available heterogeneous phantom. We used a simple simulated head and neck and prostate phantom. An ionization chamber and radiochromic film were used for meas...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371016/ https://www.ncbi.nlm.nih.gov/pubmed/30673145 http://dx.doi.org/10.1002/acm2.12535 |
_version_ | 1783394476844122112 |
---|---|
author | Yasui, Keisuke Toshito, Toshiyuki Omachi, Chihiro Hayashi, Kensuke Kinou, Hideto Katsurada, Masaki Hayashi, Naoki Ogino, Hiroyuki |
author_facet | Yasui, Keisuke Toshito, Toshiyuki Omachi, Chihiro Hayashi, Kensuke Kinou, Hideto Katsurada, Masaki Hayashi, Naoki Ogino, Hiroyuki |
author_sort | Yasui, Keisuke |
collection | PubMed |
description | The purpose of this study was to propose a verification method and results of intensity‐modulated proton therapy (IMPT), using a commercially available heterogeneous phantom. We used a simple simulated head and neck and prostate phantom. An ionization chamber and radiochromic film were used for measurements of absolute dose and relative dose distribution. The measured doses were compared with calculated doses using a treatment planning system. We defined the uncertainty of the measurement point of the ionization chamber due to the effective point of the chamber and mechanical setup error as 2 mm and estimated the dose variation base on a 2 mm error. We prepared a HU‐relative stopping power conversion table and fluence correction factor that were specific to the heterogeneous phantom. The fluence correction factor was determined as a function of depth and was obtained from the ratio of the doses in water and in the phantom at the same effective depths. In the simulated prostate plan, composite doses of measurements and calculations agreed within ±1.3% and the maximum local dose differences of each field were 10.0%. Composite doses in the simulated head and neck plan agreed within 4.0% and the maximum local dose difference for each field was 12.0%. The dose difference for each field came within 2% when taking the measurement uncertainty into consideration. In the composite plan, the maximum dose uncertainty was estimated as 4.0% in the simulated prostate plan and 5.8% in the simulated head and neck plan. Film measurements showed good agreement, with more than 92.5% of points passing a gamma value (3%/3 mm). From these results, the heterogeneous phantom should be useful for verification of IMPT by using a phantom‐specific HU‐relative stopping power conversion, fluence correction factor, and dose error estimation due to the effective point of the chamber. |
format | Online Article Text |
id | pubmed-6371016 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63710162019-02-21 Dosimetric verification of IMPT using a commercial heterogeneous phantom Yasui, Keisuke Toshito, Toshiyuki Omachi, Chihiro Hayashi, Kensuke Kinou, Hideto Katsurada, Masaki Hayashi, Naoki Ogino, Hiroyuki J Appl Clin Med Phys Radiation Oncology Physics The purpose of this study was to propose a verification method and results of intensity‐modulated proton therapy (IMPT), using a commercially available heterogeneous phantom. We used a simple simulated head and neck and prostate phantom. An ionization chamber and radiochromic film were used for measurements of absolute dose and relative dose distribution. The measured doses were compared with calculated doses using a treatment planning system. We defined the uncertainty of the measurement point of the ionization chamber due to the effective point of the chamber and mechanical setup error as 2 mm and estimated the dose variation base on a 2 mm error. We prepared a HU‐relative stopping power conversion table and fluence correction factor that were specific to the heterogeneous phantom. The fluence correction factor was determined as a function of depth and was obtained from the ratio of the doses in water and in the phantom at the same effective depths. In the simulated prostate plan, composite doses of measurements and calculations agreed within ±1.3% and the maximum local dose differences of each field were 10.0%. Composite doses in the simulated head and neck plan agreed within 4.0% and the maximum local dose difference for each field was 12.0%. The dose difference for each field came within 2% when taking the measurement uncertainty into consideration. In the composite plan, the maximum dose uncertainty was estimated as 4.0% in the simulated prostate plan and 5.8% in the simulated head and neck plan. Film measurements showed good agreement, with more than 92.5% of points passing a gamma value (3%/3 mm). From these results, the heterogeneous phantom should be useful for verification of IMPT by using a phantom‐specific HU‐relative stopping power conversion, fluence correction factor, and dose error estimation due to the effective point of the chamber. John Wiley and Sons Inc. 2019-01-23 /pmc/articles/PMC6371016/ /pubmed/30673145 http://dx.doi.org/10.1002/acm2.12535 Text en © 2019 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Radiation Oncology Physics Yasui, Keisuke Toshito, Toshiyuki Omachi, Chihiro Hayashi, Kensuke Kinou, Hideto Katsurada, Masaki Hayashi, Naoki Ogino, Hiroyuki Dosimetric verification of IMPT using a commercial heterogeneous phantom |
title | Dosimetric verification of IMPT using a commercial heterogeneous phantom |
title_full | Dosimetric verification of IMPT using a commercial heterogeneous phantom |
title_fullStr | Dosimetric verification of IMPT using a commercial heterogeneous phantom |
title_full_unstemmed | Dosimetric verification of IMPT using a commercial heterogeneous phantom |
title_short | Dosimetric verification of IMPT using a commercial heterogeneous phantom |
title_sort | dosimetric verification of impt using a commercial heterogeneous phantom |
topic | Radiation Oncology Physics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371016/ https://www.ncbi.nlm.nih.gov/pubmed/30673145 http://dx.doi.org/10.1002/acm2.12535 |
work_keys_str_mv | AT yasuikeisuke dosimetricverificationofimptusingacommercialheterogeneousphantom AT toshitotoshiyuki dosimetricverificationofimptusingacommercialheterogeneousphantom AT omachichihiro dosimetricverificationofimptusingacommercialheterogeneousphantom AT hayashikensuke dosimetricverificationofimptusingacommercialheterogeneousphantom AT kinouhideto dosimetricverificationofimptusingacommercialheterogeneousphantom AT katsuradamasaki dosimetricverificationofimptusingacommercialheterogeneousphantom AT hayashinaoki dosimetricverificationofimptusingacommercialheterogeneousphantom AT oginohiroyuki dosimetricverificationofimptusingacommercialheterogeneousphantom |